Emendo Biotherapeutics vs Nucleai
Emendo Biotherapeutics vs Nucleai, compared side by side on 22 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Emendo Biotherapeutics is on 59/100 and Nucleai on 63/100.
Where each one leads
Emendo Biotherapeutics
Leads on none of the measures we hold for both companies.
Nucleai
- our overall score: 63/100 against 59/100
- domain rating: 29/100 against 20/100
- headcount: 66 against 41
- headcount growth: -7.0% against -16.1%
- LinkedIn following: 18,902 against 5,333
At a glance
| Measure | Emendo Biotherapeutics | Nucleai |
|---|---|---|
| What it is | Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology. | AI-powered spatial biology platform for precision medicine and drug development. |
| Category | Healthcare, Genome Editing, CRISPR, Biotech | Healthcare, Oncology, Pharmaceutical, HealthTech |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Software |
| Founded | 2015 | 2018 |
| Headquarters | Tel Aviv, Israel | Tel Aviv, Israel |
| Status | Active | Active |
Size, funding and growth
| Measure | Emendo Biotherapeutics | Nucleai |
|---|---|---|
| Employees | 41 | 66 |
| Headcount growthLast 12 months | -16.1% | -7.0% |
| Total funding | $61.0M | $58.5M |
| Latest round | Series B | Series B |
| LinkedIn followers | 5,333 | 18,902 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Emendo Biotherapeutics | Nucleai |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 59/100 | 63/100 |
| Traction | 55/100 | 57/100 |
| Team | 40/100 | 70/100 |
| Community | Not published | 8/100 |
| Search visibility | 44/100 | 31/100 |
| Quality | 68/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (40/100) | D (42/100) |
| Domain ratingLink authority, 0-100 | 20/100 | 29/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Emendo Biotherapeutics | Nucleai |
|---|---|---|
| Hosting | Google Cloud | Not detected |
| CMS | WordPress | WordPress |
| Frameworks | Bootstrap | Jquery |
| Analytics | Google Tag Manager | Google Tag Manager, Linkedin Insight, Facebook Pixel |
| Support stack | Not detected | HubSpot |
Emendo Biotherapeutics vs Nucleai: common questions
Which is better, Emendo Biotherapeutics or Nucleai?
On our 0-100 score Nucleai rates higher (63/100 against 59/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 22 data points above: read the rows that match what you are buying for.
How do Emendo Biotherapeutics and Nucleai compare on the numbers?
Nucleai leads on our overall score (63/100 against 59/100), domain rating (29/100 against 20/100), headcount (66 against 41), headcount growth (-7.0% against -16.1%), LinkedIn following (18,902 against 5,333).
Read the full Emendo Biotherapeutics review and pricing or the Nucleai review and pricing. You can also browse other Emendo Biotherapeutics alternatives we track.